In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Just days after Coherus $CHRS was forced to restructure and lay off 51 staffers in the wake of the FDA’s decision to reject its application for a biosimilar of Amgen’s Neulasta, its Japanese partner on the number-two program in the pipeline is bailing out of their collaboration.
Daiichi Sankyo says that their Phase III program for CHS-0214 hit the endpoint on equivalency with Enbrel in treating rheumatoid arthritis. But:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.